ViaCell Inc. operates as a biotechnology company that enables the application of human cells as medicine. It markets ViaCord, a service through which families can preserve their baby's umbilical cord blood at the time of birth for possible future medical use in treating approximately 40 diseases, including certain blood cancers and genetic diseases. The company is also developing ViaCyte, a product candidate intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell also conducts research and development to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. Its pipeline is focused in the areas of cancer, cardiac disease, diabetes, and fertility. The company was founded in 1994 and is headquartered in Cambridge, Massachusetts. As of November 8, 2007, ViaCell Inc. is a subsidiary of PerkinElmer Inc. (NYSE:PKI).